Sensitivity, specificity, positive and negative predictive value of serum S-100 beta protein in patients with malignant melanoma

Journal of B.U.ON.

Volumn 8, Issue 2, 2003, Pages 139-141

  Vrbić, Svetislav ^a   Filipovic S ^a   Pejic I ^a   Vrbic M ^b   Filipovic A ^c  

^a Clinical Centre Nis   (Serbia)

^b Clinical Center Ni   (Serbia)

^c Faculty of Medicine of Ni   (Serbia)

Author keywords

Malignant melanoma; Negative predictive value; Positive predictive value; Sensitivity; Serum S 100 beta protein; Specificity

Indexed keywords

PROTEIN S 100; PROTEIN S 100 BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RELIABILITY; SENSITIVITY ANALYSIS; STATISTICAL MODEL;

EID: 0344444730     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schutter EMJ, Wicki R, Engelkamp D et al. Isolation of YAC clone covering a cluster of nine S-100 genes on human chromosome 1q21: Rationale for a new nomenclature of the S-100 calcium-binding protein family. Genomics 1995; 25: 638-643.
2. Wicki R, Schafer BW, Erne P et al. Characterization of the human and mouse cDNAs coding for S-100 A13, a new member of the S-100 protein family. Biochem Biophys Res Commun 1996; 227: 594-599.
3. Donato R. Perspectives in S-100 protein biology. Cell Calcium 1991; 12: 713-726.
4. Enzinger MF, Weis SW (eds). Soft Tissue Tumors (2nd edn). C.V. Mosby Co, St. Louis 1998: pp 93-96.
5. Klingman D, Hilt DC. The S-100 protein family. TIBS 1998; 13: 437-443.
6. Egan MJ, Crocker J, Newman J et al. Immunohistochemical localisation of S-100 protein in skin tumors. Arch Pathol Lab Med 1986; 110: 765-767.
7. Cho KN, Hashimoto K, Taniguchi Y et al. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990; 66: 765-771.
8. Bonfrer J, Korse C, Nieweg O et al. The luminescence immunoassay S-100: A sensitive test to measure circulating S-100 beta. Br J Cancer 1988; 77: 2210-2214.
9. Bariger SW, Wolchok SR, Van Eldik LJ. Disulfide-linked S-100 beta dimmers and signal transduction. Biochem Biophys Acta 1992; 11: 105-112.
10. Fagrant O, Sindic C, Laterre C. Particle counting immunoassay of S-100 protein in serum: Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 1988; 34: 1387-1391.
11. Persson L, Hardmark HG, Gustaffson J. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum, markers of cell damage in human central nervous system. Stroke 1987; 18: 911-918.
12. Kaskel P, Berking C, Sander S et al. S-100 protein in peripheral blood: A marker for melanoma metastases: A prospective 2-center study. J Am Acad Dermatol 1999; 41: 962-969.
13. Armstrong BK, Cricker A. Cutaneous melanoma. Cancer Surv 1994; 19: 219-224.
14. Balch CM, Cascinelli N, Drzewiecki KT et al. A comparison of prognostic factors worldwide. In: Balch CM, Houghton AN, Milton GW (eds). Cutaneous Melanoma. Philadelphia, JB Lippincot, 1985: pp 221-247.
15. Lee JAH. The causation of melanoma. In: Balch CM, Houghton AN, Milton GW (eds). Cutaneous Melanoma. Philadelphia, JB Lippincot, 1985: pp 303-329.
16. Balch CM, Soong SJ, Shaw HM et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW (eds). Cutaneous Melanoma (2nd edn). Philadelphia, JB Lippincot, 1992; pp 200-221.